The company said, “Immutep continued to prudently manage its cashflow over the first quarter of the new financial year while strategically investing into clinical trial programs for efti. With a cash and cash equivalent balance as at 30 September 2023 of approximately $110.1 million, Immutep’s cash position remains very strong with an expected cash reach till early CY2026. The Company has sufficient capital to reach key milestones that will potentially add value to efti and IMP761.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMMP:
- Immutep receives A$1,134,882 R&D tax incentive
- Immutep reports clinical data from INSIGHT-003 trial
- Immutep announces new data from TACTI-002 / KEYNOTE-798 Phase II trial
- Immutep announces regulatory authorization for eftilagimod alpha manufacturing
- Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use
